目的 探討納米磁藥物靶向治療膽管移植瘤組織中凋亡相關(guān)基因caspase-3的表達(dá)。方法 建立荷人膽管癌裸鼠模型，隨機(jī)分為空白對(duì)照組、納米磁藥物組(藥物濃度為250 mg/kg)、納米磁藥物靶向A組(藥物濃度為150 mg/kg)和納米磁藥物靶向B組(藥物濃度為250 mg/kg)； 取治療后第21 d的各組腫瘤組織用免疫組化及RT-PCR法測(cè)量其中caspase-3的蛋白及mRNA表達(dá)量并進(jìn)行分析。結(jié)果 納米磁藥物靶向B組中caspase-3的表達(dá)量最高,其次依次為納米磁藥物靶向A組、納米磁藥物組，空白對(duì)照組幾乎沒有caspase-3蛋白及mRNA的表達(dá)，且各組間差異均有統(tǒng)計(jì)學(xué)意義（P＜0.05)。結(jié)論 磁靶向治療腫瘤后能引起更多凋亡相關(guān)基因caspase-3表達(dá)，并且隨納米磁藥物劑量增加，caspase-3表達(dá)增多。
引用本文： 李宏,鄭建偉,唐滔,鄒聲泉. caspase-3在納米磁藥物靶向治療膽管移植瘤組織中的表達(dá). 中國普外基礎(chǔ)與臨床雜志, 2006, 13(6): 685-688. doi: 復(fù)制
| 1. | Twomey C, McCarthy JV. Pathways of apoptosis and importance in development [J]. J Cell Mol Med, 2005; 9(2)∶345. |
| 2. | Aoyagi T, Okano T. Targeting of anticancer drug using intelligent polymers [J]. Nippon Rinsho, 1998; 56(3)∶644. |
| 3. | Senyei AE, Widder KJ. Drug targeting: magnetically responsive albumin microspheres——a review of the system to date [J]. Gynecol Oncol, 1981; 12(1)∶1. |
| 4. | 呂 軍, 楊連粵, 楊建青. 5-氟尿嘧啶誘導(dǎo)肝癌細(xì)胞凋亡過程中 caspase-3活性變化的研究 [J]. 中華實(shí)驗(yàn)外科雜志， 2000； 17（5）∶401. |
| 5. | Widder KJ, Marino PA, Morris RM, et al. Selective targeting of magnetic albumin microspheres to the Yoshida sarcoma: ultrastructural evaluation of microsphere disposition [J]. Eur J Cancer Clin Oncol, 1983; 19(1)∶141. |
| 6. | Zou W, Zeng J, Zhou M, et al. Involvement of caspase-3 and p38 mitogen-activated protein kinase in cobalt chloride-induced apoptosis in PC12 cells [J]. J Neurosci Res, 2002; 67(6)∶837. |
| 7. | Fernandes-Alnemri T, Litwack G, Alnemri ES. CPP32, a novel human apoptotic protein with homology to Caenorhabditis elegans cell death protein Ced-3 and mammalian interleukin-1 beta-converting enzyme [J].J Biol Chem, 1994; 269(49)∶30761. |
| 8. | Cosulich SC, Savory PJ, Clarke PR. Bcl-2 regulates amplification of caspase activation by cytochrome c[J]. Curr Biol, 1999; 9(3)∶147. |
| 9. | Yeh JH, Hsu SC, Han SH, et al. Mitogen-activated protein kinase kinase antagonized fas-associated death domain protein-mediated apoptosis by induced FLICE-inhibitory protein expression [J]. J Exp Med, 1998; 188(10)∶1795. |
- 1. Twomey C, McCarthy JV. Pathways of apoptosis and importance in development [J]. J Cell Mol Med, 2005; 9(2)∶345.
- 2. Aoyagi T, Okano T. Targeting of anticancer drug using intelligent polymers [J]. Nippon Rinsho, 1998; 56(3)∶644.
- 3. Senyei AE, Widder KJ. Drug targeting: magnetically responsive albumin microspheres——a review of the system to date [J]. Gynecol Oncol, 1981; 12(1)∶1.
- 4. 呂 軍, 楊連粵, 楊建青. 5-氟尿嘧啶誘導(dǎo)肝癌細(xì)胞凋亡過程中 caspase-3活性變化的研究 [J]. 中華實(shí)驗(yàn)外科雜志， 2000； 17（5）∶401.
- 5. Widder KJ, Marino PA, Morris RM, et al. Selective targeting of magnetic albumin microspheres to the Yoshida sarcoma: ultrastructural evaluation of microsphere disposition [J]. Eur J Cancer Clin Oncol, 1983; 19(1)∶141.
- 6. Zou W, Zeng J, Zhou M, et al. Involvement of caspase-3 and p38 mitogen-activated protein kinase in cobalt chloride-induced apoptosis in PC12 cells [J]. J Neurosci Res, 2002; 67(6)∶837.
- 7. Fernandes-Alnemri T, Litwack G, Alnemri ES. CPP32, a novel human apoptotic protein with homology to Caenorhabditis elegans cell death protein Ced-3 and mammalian interleukin-1 beta-converting enzyme [J].J Biol Chem, 1994; 269(49)∶30761.
- 8. Cosulich SC, Savory PJ, Clarke PR. Bcl-2 regulates amplification of caspase activation by cytochrome c[J]. Curr Biol, 1999; 9(3)∶147.
- 9. Yeh JH, Hsu SC, Han SH, et al. Mitogen-activated protein kinase kinase antagonized fas-associated death domain protein-mediated apoptosis by induced FLICE-inhibitory protein expression [J]. J Exp Med, 1998; 188(10)∶1795.